Coder-rony commited on
Commit
443065d
·
verified ·
1 Parent(s): 59be688

log update

Browse files
Files changed (1) hide show
  1. log.txt +245 -0
log.txt CHANGED
@@ -150977,3 +150977,248 @@ original_reason_len=17
150977
  ]
150978
  }
150979
  ======================================================================
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
150977
  ]
150978
  }
150979
  ======================================================================
150980
+
150981
+ ======================================================================
150982
+ [GENERATE] atlas-631b2c17e8 | 2026-08-18 12:44:24
150983
+ seed_type=wikitext | structural=FAIL: step 0 missing 'action'
150984
+ ----------------------------------------------------------------------
150985
+ {
150986
+ "task_instruction": "Determine the prognosis for a patient with AML based on their cytogenetic abnormalities.",
150987
+ "steps": [
150988
+ {
150989
+ "observation": "The patient has AML.",
150990
+ "reasoning": "Given that AML is the disease in question, we need to consider the cytogenetic abnormalities to determine prognosis."
150991
+ },
150992
+ {
150993
+ "observation": "Cytogenetics is the primary factor in prognosis for AML.",
150994
+ "reasoning": "Cytogenetics, which refers to the chromosomal structure of the leukemic cells, is the most important factor in predicting the outcome of AML treatment."
150995
+ },
150996
+ {
150997
+ "observation": "The patient's cytogenetic profile is normal.",
150998
+ "reasoning": "If the patient has 'normal' cytogenetics, they fall into the intermediate risk group."
150999
+ },
151000
+ {
151001
+ "observation": "Normal cytogenetics correspond to an intermediate risk group.",
151002
+ "reasoning": "This means the patient's prognosis is neither as favorable as those with specific abnormalities like (15;17) translocation nor as poor as those with other abnormalities."
151003
+ }
151004
+ ]
151005
+ }
151006
+ </think>
151007
+
151008
+ {
151009
+ "task_instruction": "Determine the prognosis for a patient with AML based on their cytogenetic abnormalities.",
151010
+ "steps": [
151011
+ {
151012
+ "observation": "The patient has AML.",
151013
+ "reasoning": "Given that AML is the disease in question, we need to consider the cytogenetic abnormalities to determine prognosis."
151014
+ },
151015
+ {
151016
+ "observation": "Cytogenetics is the primary factor in prognosis for AML.",
151017
+ "reasoning": "Cytogenetics, which refers to the chromosomal structure of the leukemic cells, is the most important factor in predicting the outcome of AML treatment."
151018
+ },
151019
+ {
151020
+ "observation": "The patient's cytogenetic profile is normal.",
151021
+ "reasoning": "If the patient has 'normal' cytogenetics, they fall into the intermediate risk group."
151022
+ },
151023
+ {
151024
+ "observation": "Normal cytogenetics correspond to an intermediate risk group.",
151025
+ "reasoning": "This means the patient's prognosis is neither as favorable as those with specific abnormalities like (15;17) translocation nor as poor as those with other abnormalities."
151026
+ }
151027
+ ]
151028
+ }
151029
+ ======================================================================
151030
+
151031
+ ======================================================================
151032
+ [GENERATE] atlas-7b452149ff | 2026-08-18 12:45:06
151033
+ seed_type=wikitext | structural=PASS
151034
+ ----------------------------------------------------------------------
151035
+ {
151036
+ "task_instruction": "Determine the prognosis of a patient with secondary AML arising from chemotherapy for a previous malignancy.",
151037
+ "steps": [
151038
+ {
151039
+ "observation": "The patient has secondary AML resulting from chemotherapy treatment for a previous malignancy.",
151040
+ "reasoning": "Secondary AML, which arises after chemotherapy, is mentioned to have a worse prognosis.",
151041
+ "action": "Recognize that the prognosis is worse due to the nature of secondary AML."
151042
+ },
151043
+ {
151044
+ "observation": "The passage also notes that secondary AML is associated with a high rate of unfavorable cytogenetic abnormalities.",
151045
+ "reasoning": "Unfavorable cytogenetic abnormalities are linked to a poorer prognosis in AML patients.",
151046
+ "action": "Conclude that the unfavorable chromosomal changes contribute to the worse outcome."
151047
+ }
151048
+ ]
151049
+ }
151050
+
151051
+ </think>
151052
+
151053
+ {
151054
+ "task_instruction": "Determine the prognosis of a patient with secondary AML arising from chemotherapy for a previous malignancy.",
151055
+ "steps": [
151056
+ {
151057
+ "observation": "The patient has secondary AML resulting from chemotherapy treatment for a previous malignancy.",
151058
+ "reasoning": "Secondary AML, which arises after chemotherapy, is mentioned to have a worse prognosis.",
151059
+ "action": "Recognize that the prognosis is worse due to the nature of secondary AML."
151060
+ },
151061
+ {
151062
+ "observation": "The passage also notes that secondary AML is associated with a high rate of unfavorable cytogenetic abnormalities.",
151063
+ "reasoning": "Unfavorable cytogenetic abnormalities are linked to a poorer prognosis in AML patients.",
151064
+ "action": "Conclude that the unfavorable chromosomal changes contribute to the worse outcome."
151065
+ }
151066
+ ]
151067
+ }
151068
+ ======================================================================
151069
+
151070
+ ======================================================================
151071
+ [GENERATE] atlas-9b31797527 | 2026-08-18 12:46:01
151072
+ seed_type=wikitext | structural=PASS
151073
+ ----------------------------------------------------------------------
151074
+ {
151075
+ "task_instruction": "Determine the factors that influence prognosis in a patient with cancer.",
151076
+ "steps": [
151077
+ {
151078
+ "observation": "The passage mentions that age over 60 years is associated with poorer outcomes.",
151079
+ "reasoning": "Age being a factor suggests that older patients might have weaker bodies, making them less able to handle treatments.",
151080
+ "action": "Note that age over 60 is a significant factor in prognosis."
151081
+ },
151082
+ {
151083
+ "observation": "It also states that elevated lactate dehydrogenase levels are linked to poorer outcomes.",
151084
+ "reasoning": "High LDH levels can indicate tissue damage or disease progression, which would negatively impact prognosis.",
151085
+ "action": "Identify elevated LDH levels as another critical factor."
151086
+ },
151087
+ {
151088
+ "observation": "Performance status, which includes physical condition and activity level, is highlighted as a major factor.",
151089
+ "reasoning": "A person's ability to perform daily activities can reflect their overall health and how well they can withstand treatment.",
151090
+ "action": "Recognize performance status as a key determinant of prognosis."
151091
+ }
151092
+ ]
151093
+ }
151094
+ </think>
151095
+
151096
+ {
151097
+ "task_instruction": "Identify the factors influencing the prognosis of a cancer patient.",
151098
+ "steps": [
151099
+ {
151100
+ "observation": "The passage states that age over 60 years is associated with poorer outcomes.",
151101
+ "reasoning": "Advanced age may lead to reduced physiological resilience, impacting treatment efficacy and recovery potential.",
151102
+ "action": "Conclude that age over 60 is a significant factor in prognosis."
151103
+ },
151104
+ {
151105
+ "observation": "Elevated lactate dehydrogenase levels are linked to poorer outcomes.",
151106
+ "reasoning": "High LDH levels often indicate tissue damage or disease severity, which can worsen prognosis.",
151107
+ "action": "Identify elevated LDH as a critical factor affecting prognosis."
151108
+ },
151109
+ {
151110
+ "observation": "Performance status, encompassing physical condition and activity level, is a major factor.",
151111
+ "reasoning": "A patient's ability to perform daily activities reflects their overall health and capacity to handle treatments, thereby influencing prognosis.",
151112
+ "action": "Recognize performance status as a key determinant of prognosis."
151113
+ }
151114
+ ]
151115
+ }
151116
+ ======================================================================
151117
+
151118
+ ======================================================================
151119
+ [GENERATE] atlas-4364c0520d | 2026-08-18 12:47:33
151120
+ seed_type=wikitext | structural=PASS
151121
+ ----------------------------------------------------------------------
151122
+ {
151123
+ "task_instruction": "Determine the impact of FLT3 ITD mutations on the prognosis of AML patients with normal cytogenetics.",
151124
+ "steps": [
151125
+ {
151126
+ "observation": "FLT3 ITD mutations are mentioned in the passage.",
151127
+ "reasoning": "The passage states that FLT3 ITD mutations have been shown to confer a poorer prognosis in AML with normal cytogenetics.",
151128
+ "action": "Identify that FLT3 ITD mutations negatively impact prognosis."
151129
+ },
151130
+ {
151131
+ "observation": "The impact is specifically noted for patients with normal cytogenetics.",
151132
+ "reasoning": "The text highlights that this poorer prognosis is observed in AML patients with normal cytogenetics.",
151133
+ "action": "Confirm that the prognosis impact is specific to this group."
151134
+ }
151135
+ ]
151136
+ }
151137
+
151138
+ Okay, I need to figure out how to create a realistic question based on the given passage about molecular alterations in AML. The passage talks about several mutations like FLT3 ITD, NPM1, CEBPA, and c-KIT, and how some of them are included in validated risk stratification schemas. It also mentions that FLT3 ITD is linked to a poorer prognosis in AML with normal cytogenetics, and that some inhibitors have been tested with mixed results. Additionally, NPM1 and biallelic CEBPA are associated with better outcomes.
151139
+
151140
+ So, a good question would require someone to reason through which mutations are linked to better or worse outcomes and perhaps identify which ones are part of the validated schemas. Maybe the question could ask about the prognosis impact of specific mutations in AML patients with normal cytogenetics.
151141
+
151142
+ I should structure the JSON with a task instruction that clearly states the goal, like determining the impact of certain mutations on prognosis. Then, the steps should logically flow from identifying the mutations mentioned, understanding their impact, and confirming their inclusion in risk stratification schemas.
151143
+
151144
+ Each step should start with a different observation and reasoning to avoid repetition. For example, first, observe that FLT3 ITD is mentioned, then note its impact on prognosis, then confirm its inclusion in the schemas. Similarly, for NPM1 and CEBPA, observe their association, reason about their impact, and confirm their inclusion.
151145
+
151146
+ I need to make sure each action is clear and leads to the next step, ultimately providing a complete answer about which mutations improve or worsen the prognosis in AML patients with normal cytogenetics.
151147
+ </think>
151148
+
151149
+ ```json
151150
+ {
151151
+ "task_instruction": "Identify the mutations associated with improved or worsened prognosis in AML patients with normal cytogenetics and determine their inclusion in validated risk stratification schemas.",
151152
+ "steps": [
151153
+ {
151154
+ "observation": "The passage mentions FLT3 ITD, NPM1, CEBPA, and c-KIT as molecular alterations under study for their prognostic impact in AML.",
151155
+ "reasoning": "FLT3 ITD is linked to a poorer prognosis, while NPM1 and biallelic CEBPA are associated with improved outcomes, especially in patients with normal cytogenetics.",
151156
+ "action": "Identify that FLT3 ITD worsens prognosis, while NPM1 and CEBPA improve it."
151157
+ },
151158
+ {
151159
+ "observation": "These mutations are part of validated international risk stratification schemas.",
151160
+ "reasoning": "The passage states that NPM1 and CEBPA are used in current risk stratification algorithms, indicating their inclusion in validated schemas.",
151161
+ "action": "Confirm that NPM1 and CEBPA are included in validated schemas, while FLT3 ITD's inclusion is not explicitly stated but implied by its prognostic impact."
151162
+ }
151163
+ ]
151164
+ }
151165
+ ```
151166
+ ======================================================================
151167
+
151168
+ ======================================================================
151169
+ [GENERATE] atlas-6383871180 | 2026-08-18 12:48:52
151170
+ seed_type=wikitext | structural=PASS
151171
+ ----------------------------------------------------------------------
151172
+ {
151173
+ "task_instruction": "Identify the factors that influence the clinical significance of c-KIT mutations in AML and explain their importance.",
151174
+ "steps": [
151175
+ {
151176
+ "observation": "c-KIT mutations are prevalent in AML.",
151177
+ "reasoning": "The passage states that c-KIT mutations are prevalent, which suggests they are significant in the disease context.",
151178
+ "action": "Recognize prevalence as a key factor."
151179
+ },
151180
+ {
151181
+ "observation": "Tyrosine kinase inhibitors like imatinib and sunitinib are available.",
151182
+ "reasoning": "The availability of these inhibitors indicates that c-KIT mutations can be targeted therapeutically, enhancing clinical significance.",
151183
+ "action": "Note the therapeutic implications of c-KIT mutations."
151184
+ },
151185
+ {
151186
+ "observation": "Additional markers like RUNX1, ASXL1, and TP53 are associated with poor outcomes.",
151187
+ "reasoning": "The inclusion of these markers in recommendations suggests they play a role in prognosis, which ties into the clinical significance of c-KIT mutations.",
151188
+ "action": "Understand the role of other markers in prognosis."
151189
+ },
151190
+ {
151191
+ "observation": "The prognostic importance of other genes like DNMT3A, IDH1, IDH2 is less clear.",
151192
+ "reasoning": "While these genes are mutated, their impact on prognosis isn't as established, highlighting that c-KIT mutations have a more defined role.",
151193
+ "action": "Acknowledge the uncertainty around other genes' prognostic value."
151194
+ }
151195
+ ]
151196
+ }
151197
+ </think>
151198
+
151199
+ {
151200
+ "task_instruction": "Identify the factors that influence the clinical significance of c-KIT mutations in AML and explain their importance.",
151201
+ "steps": [
151202
+ {
151203
+ "observation": "c-KIT mutations are prevalent in AML.",
151204
+ "reasoning": "The passage states that c-KIT mutations are prevalent, which suggests they are significant in the disease context.",
151205
+ "action": "Recognize prevalence as a key factor."
151206
+ },
151207
+ {
151208
+ "observation": "Tyrosine kinase inhibitors like imatinib and sunitinib are available.",
151209
+ "reasoning": "The availability of these inhibitors indicates that c-KIT mutations can be targeted therapeutically, enhancing clinical significance.",
151210
+ "action": "Note the therapeutic implications of c-KIT mutations."
151211
+ },
151212
+ {
151213
+ "observation": "Additional markers like RUNX1, ASXL1, and TP53 are associated with poor outcomes.",
151214
+ "reasoning": "The inclusion of these markers in recommendations suggests they play a role in prognosis, which ties into the clinical significance of c-KIT mutations.",
151215
+ "action": "Understand the role of other markers in prognosis."
151216
+ },
151217
+ {
151218
+ "observation": "The prognostic importance of other genes like DNMT3A, IDH1, IDH2 is less clear.",
151219
+ "reasoning": "While these genes are mutated, their impact on prognosis isn't as established, highlighting that c-KIT mutations have a more defined role.",
151220
+ "action": "Acknowledge the uncertainty around other genes' prognostic value."
151221
+ }
151222
+ ]
151223
+ }
151224
+ ======================================================================